By Fineline Cube 
AbbVie (NYSE: ABBV) announced financial results for the second quarter (Q2) of 2026.
Financial Performance Summary
| Metric | Q2 2026 | Change |
|---|---|---|
| Worldwide Net Revenues | USD 16.990 billion | +10.2% |
| Adjusted Diluted EPS Guidance (Full Year 2026) | USD 13.87 – USD 14.07 | Updated from USD 13.91 – USD 14.11 |
Business Segment Performance
Immunology Portfolio
- Total Revenue: USD 8.786 billion (+15.1%)
- Skyrizi (Risankizumab): USD 5.505 billion (+24.4%)
- Rinvoq (Upadacitinib): USD 2.525 billion (+24.5%)
- Humira (Adalimumab): USD 756 million (+35.9%)
Neuroscience Portfolio
- Total Revenue: USD 3.228 billion (+20.3%)
- Vraylar (Cariprazine): USD 1.071 billion (+18.9%)
- Botox Therapeutic: USD 1.042 billion (+12.2%)
- Ubrelvy (Ubrogepant): USD 392 million (+16.0%)
- Qulipta (Atogepant): USD 350 million (+30.9%)
Oncology Portfolio
- Total Revenue: USD 1.650 billion (-1.5%)
- Venclexta (Venetoclax): USD 771 million (+11.6%)
- Imbruvica (Ibrutinib): USD 532 million (-29.4%)
- Elahere (Mirvetuximab Soravtansine): USD 211 million (+33.1%)
Aesthetics Portfolio
- Total Revenue: USD 1.282 billion (+0.3%)
- Botox Cosmetic: USD 728 million (+5.2%)
- Juvederm: USD 245 million (-6.0%)
Strategic Significance
AbbVie’s Q2 2026 performance demonstrates the company’s successful diversification strategy beyond its legacy Humira franchise. The immunology portfolio continues to show exceptional growth with a 15.1% increase, driven by strong performances from next-generation assets Skyrizi and Rinvoq, which collectively generated USD 8.03 billion in revenue.
The neuroscience portfolio showed robust 20.3% growth, highlighting AbbVie’s expanding presence in this therapeutic area. While the oncology portfolio experienced a slight 1.5% decline overall, newer assets like Elahere (+33.1%) and Venclexta (+11.6%) demonstrated strong growth, partially offsetting the decline in Imbruvica.
Updated Full-Year Guidance
To include the impact of the proposed Apogee Therapeutics acquisition, AbbVie is updating its adjusted diluted EPS guidance range for the full year 2026 from USD 13.91 – USD 14.11 to USD 13.87 – USD 14.07.
Market Context & Competitive Positioning
- Immunology Leadership: AbbVie maintains dominant market position with continued strong growth in Skyrizi and Rinvoq
- Portfolio Diversification: Successful expansion into neuroscience and aesthetics reduces dependency on any single therapeutic area
- Oncology Transition: Managing the transition from mature assets like Imbruvica to next-generation therapies
- Strategic Acquisitions: Proposed Apogee Therapeutics acquisition reflects commitment to pipeline innovation
Company Statement
“Our second quarter results reflect the strength of our diversified portfolio and our ability to execute across multiple therapeutic areas,” said Robert A. Michael, Chief Executive Officer of AbbVie. “The exceptional performance of our immunology franchise, combined with strong growth in neuroscience and promising early data from our pipeline, positions us well for sustained long-term growth.”
Forward-Looking Statements
This brief contains forward-looking statements regarding financial performance, growth expectations, business outlook, and the proposed Apogee Therapeutics acquisition. Actual results may differ due to market dynamics, competitive pressures, regulatory developments, integration risks, and other risk factors.-Fineline Info & Tech